4/12
Powered by Foleon

Create the content your audience craves.

Find out more
  • Pages
  • Editions
01 Welcome
02 Introduction
03 #1 DEP and AI
04 #2 Radiogligand
05 #3 Living Cancer Cell Liquid
06 #4 Solid Tumor
07 #5 AI Driven SaaS
08 #6 Nanoparticles Reprogram
09 #7 Dual Checkpoint
10 #8 Approved HER2
11 #9 Biosimilar
12 #10 Big Data

#2 Radioligand Therapy (RTL) Drug Approval for “See & Treat”

Oncology Advancements: Top 10 of 2022

Clinical trials showed a 38% increase in survival in PSMA-positive metastatic castration-resistant prostate cancer patients (who had been treated with AR pathways & taxane-based chemotherapy)[2].

Why is this significant?

RTL offers the promise of “see and treat”, while also being less invasive and sparing normal tissue.

RTL has the potential to combine different kinds of radioactive atoms and targeting molecules together. By combining a radioactive atom that can identify the tumors location with a therapeutic that is armed to damage the tumor cell, new combinations can be used for expansion of ”see and treat” therapy.

What is RTL?

Nuclear medicine has both diagnostic imaging and therapeutic components, called radioligand imaging and radioligand therapy. Both use the same targeting approach. The diagnostic imaging component delivers radioactive atoms that have the potential to reveal tumor locations, while the therapeutic component delivers radioactive particles that have the potential to damage cells.

[1]

The FDA approved Pluvicto®, a first in its class targeted radioligand to treat metastatic prostate cancer patients, representing a leap in the use of Precision Nuclear Medicine.

Sources:

Pluvicto™ is a registered trademark by Novartis as the first targeted radioligand therapy for the treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer.

1. Radioligand Therapy Discovering and developing nuclear medicine for cancer
2. Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer